Poll

How do you manage patients with refractory OAB?

Usually refer to another urologist for InterStim
Usually refer to another urologist for PTNS
Usually refer to another urologist for onabotulinumA (Botox)
Usually manage myself
Other
Related Videos
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
Investigators characterize vibegron prescribing patterns for OAB
Colin Goudelocke, MD, answers a question during a Zoom video interview
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Smaller size, patient control advantages of neurostimulator for OAB
Batteryless neurostimulator found efficacious at 6-month follow-up
Batteryless neurostimulator found efficacious at 6-month follow-up
Colin Goudelocke, MD, answers a question during a Zoom video interview
Colin Goudelocke, MD, on 6-month data for batteryless neurostimulator
Vanita Gaglani, RPT, answers a question during a video interview
A physical therapist’s advice for men with post-prostatectomy incontinence
William Furuyama, MD, answers a question during a Zoom video interview
William Furuyama, MD, on community factors’ influence on urinary incontinence
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Investigators explore social vulnerability and urinary incontinence
Vanita Gaglani, RPT, answers a question during a video interview
Vanita Gaglani, RPT, discusses books on post-prostatectomy incontinence and prostatitis
Related Content
Gene therapy shows encouraging efficacy for overactive bladder
April 8th 2025

Gene therapy shows encouraging efficacy for overactive bladder

Hannah Clarke
At week 12, patients in the URO-902 cohorts demonstrated significantly greater improvements in daily microuritions vs placebo.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
FDA grants 510(k) clearance to Glean Urodynamics System
April 2nd 2025

FDA grants 510(k) clearance to Glean Urodynamics System

Hannah Clarke
"Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI
March 4th 2025

FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI

Hannah Clarke
The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.
Pivotal study data show efficacy of percutaneous SNM device for UUI
February 28th 2025

Pivotal study data show efficacy of percutaneous SNM device for UUI

Hannah Clarke
Overall, 84.2% of patients achieved a 50% or greater reduction in urgent leaks.
© 2025 MJH Life Sciences

All rights reserved.